HEALTH CARE

Wellcome Shares Fall on AIDS Drug Study: Shares in British pharmaceutical company Wellcome fell after a major study found that its ground-breaking anti-AIDS drug, AZT, did not halt the onset of AIDS in people with HIV, the virus that causes AIDS. Wellcome shares trading in the United States fell 62.5 cents to $10.625 on the New York Stock Exchange. Nearly 40% of AZT sales are for people not yet suffering AIDS symptoms. AZT, also known as Retrovir, accounted for just under 13% of Wellcome group sales of $1.55 billion in the six months ended February, 1993.